Nasdaq

Trevi Therapeutics Announces Positive Outcome of the Sample Size Re-Estimation Analysis in PRISM Trial for Severe Pruritus in Patients With Prurigo Nodularis

NEW HAVEN, Conn., July 13, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio ...
Morningstar

Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic ...

The trial has reached 75% of the targeted enrollment, and topline results continue to be expected in the first half of 2025 NEW HAVEN, Conn., Dec. 12, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc.
Seeking Alpha

Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment

Global Phase 3 LEVEL-2 Study Initiated; Company Estimates Completion of Enrollment by End of 2027 CHAPEL HILL, N.C., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (TENX) (“Tenax” or ...
Hosted on MSN

Tenax Therapeutics reports result of prespecified blinded sample size assessment

Tenax Therapeutics (TENX) announced that the prespecified Blinded Sample Size Re-estimation of LEVEL demonstrated the trial is powered at well over 90% to detect a 25 meter change in 6-minute walk ...